C-peptide vs IGF-1 LR3
Head-to-head comparison of C-peptide (Connecting peptide (C-peptide)) and IGF-1 LR3 (Insulin-like Growth Factor-1 Long R3) — benefits, dosing, side effects, research data, and where to buy.
| Property | C-peptide | IGF-1 LR3 |
|---|---|---|
| Category | Pain Management | Performance |
| Full Name | Connecting peptide (C-peptide) | Insulin-like Growth Factor-1 Long R3 |
| Molecular Weight | 3020.3 Da | 9,117 Da |
| Half-Life | ~20-30 min | ~20-30 hours |
| Amino Acids | 31 | 83 |
| Typical Dose | no approved analgesic dose|research-only | 20-100 mcg |
| Route | IV|subQ | IM / SC |
| Purity | ≥98% | — |
| Studies Count | 46 | 298 |
| Research Status | Pre-clinical | Pre-clinical |
C-peptide Benefits
- ✓diabetic neuropathy research
- ✓nerve function support
- ✓possible analgesic effect
IGF-1 LR3 Benefits
- ✓Promotes muscle hyperplasia (new muscle cells)
- ✓Extended half-life vs native IGF-1
- ✓Enhanced protein synthesis
- ✓Improved nutrient partitioning
- ✓Anti-catabolic effects
C-peptide Dosing
0.5-1.0 mg/day in research|route varies by protocol
IGF-1 LR3 Dosing
Standard: 20-50 mcg IM post-workout|Advanced: 50-100 mcg IM or SC daily|Cycle: 4-6 weeks on, 4 weeks off
C-peptide Side Effects
- ⚠injection-site reactions
- ⚠unknown long-term safety
IGF-1 LR3 Side Effects
- ⚠Common: Hypoglycemia (dose-dependent), joint pain, water retention
- ⚠Moderate: Gut growth concern (high doses), acromegaly-like symptoms
- ⚠Serious: Theoretical cancer risk (prolonged high-dose use)
Research Overview
C-peptide
C-peptide is not an approved analgesic, but multiple studies have examined its effects on peripheral nerve blood flow and neuropathy outcomes. The strongest relevance is in diabetic neuropathic pain rather than migraine.
IGF-1 LR3
IGF-1 LR3 has extensive in vitro and animal data. Its role in muscle hyperplasia is well-documented. The extended half-life modification provides practical advantages over native IGF-1.
Ready to buy?
Find both peptides from our verified, lab-tested vendors with purity certificates and third-party testing.